The investor of a European early-stage biotech company developing a first-in-class oral therapy for Alzheimer’s disease engaged DIAMANTE to support the validation and execution of the discovery and preclinical development strategy in preparation for Series A financing.
DIAMANTE worked closely with the virtual project team to establish and continuously refine an integrated discovery plan. This plan covered in silico modelling, medicinal chemistry, and in vitro and in vivo pharmacology, with the goal of identifying a lead compound. Together with the team, DIAMANTE identified, selected, and managed a network of specialized CRO partners and external experts.
Further, based on the optimized scientific narrative, target product profile, and biomarker strategy, DIAMANTE designed the first-in-human development path. This included detailed timelines and resource estimates for all required IND-enabling studies.
This comprehensive support enabled the client’s Series A fundraising efforts and formed the core of an NIH grant application.